Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: Is the synergy worth the risk?

Stephen B. Hanauer*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

40 Scopus citations

Abstract

Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicify, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.

Original languageEnglish (US)
Pages (from-to)1181-1183
Number of pages3
JournalGut
Volume56
Issue number9
DOIs
StatePublished - Sep 2007

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: Is the synergy worth the risk?'. Together they form a unique fingerprint.

Cite this